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Abstract 5-(l-Azidovinyl)-2'-deoxyuridine (AzVDU) and a se- 
ries of 5-[1-azido-2-halogenoethyl]-derivatives of i~-D-arabinofu- 
ranosyluracil (AU) proved markedly inhibitory to the replication 
of herpes simplex virus type 1 (HSV-1) and varicella zoster virus 
(VZV), but not thymidine kinase (TK)-deficient HSV-I and VZV 
strains. None of the compounds were cytostatic. However, 
AzVDU, but not the 5-[1-azido-2-halogenoethyl]-AU derivatives 
became highly cytostatic against HSV-1 and HSV-2 TK gene- 
transfected FM3A tumor cells. The molecular target for the 
cytostatie ffect of AzVDU proved to be thymidylate synthase. 
Short exposure of AzVDU-treated FM3A TK-/HSV-1 TK + cells 
to irradiation at A -- 254 nm enhanced the cytostatic activity of 
AzVDU by 5-fold. 
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1. Introduction 
We have recently reported that selective anti-herpetic agents 
such as (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU, brivud- 
ine) [1 3] and various related erivatives of BVDU (i.e. (E)-5- 
(2-iodovinyl)-2'-deoxyuridine (IVDU) (1), (E)-5-(2-bromo- 
vinyl)-2'-deoxy-4'-thiouridine (S-BVDU) [4], 2'-fluoro-substi- 
tuted IVDU (IVFRU) [5] and 5-(furan-2-yl- and thien-2-yl)- 
substituted derivatives of 2'-deoxyuridine [6]) exhibit a mark- 
edly increased cytostatic activity against murine mammary car- 
cinoma FM3A cells transfected with the HSV-1 or HSV-2 thy- 
midine kinase (TK) gene. We also demonstrated that the cyto- 
static activity of these anti-herpetic drugs against HSV TK 
gene-transfected umor cells is based on the inhibition of thy- 
midylate synthase (TS) [2-6]. In 1980, we demonstrated that 
thymidylate synthase is susceptible to photoaffinity labelling 
upon administration f light-exposed (E)-5-(3-azidostyryl)-2'- 
deoxyuridine, a compound that provides ahighly reactive func- 
tional group which interacts with the bound TS enzyme to give 
enzyme-inactivation [7].Based on: (i) the current interest in 
anti-herpetic compounds that can be applied as chemother- 
apeutic agents against umor cells in which the thymidine ki- 
nase gene of herpes implex virus has been introduced [8 12]; 
(ii) the identification of thymidylate synthase as the target en- 
zyme for the cytostatic activity of BVDU and related com- 
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pounds against HSV TK gene-transfected umor cells [1-6]; and 
(iii) our observations that thymidylate synthase may become 
susceptible to irreversible inactivation by light-exposed azido- 
substituted 2'-deoxyuridine analogues [7], we designed several 
novel azido-substituted 2'-deoxyuridine analogues and evalu- 
ated their anti-herpetic and cytostatic activity against HSV TK 
gene-transfected FM3A tumor cells. We found 5-(1-azido- 
vinyl)-2'-deoxyuridine (AzVDU) to be a potent andnon-toxic 
anti-herpetic compound that showed a markedly increased cy- 
tostatic activity against HSV TK gene-transfected umor cells. 
This cytostatic activity could further be enhanced upon short 
irradiation of the drug-treated tumor cells at A = 254 nm. 
2. Materials and methods 
2.1. Cells 
FM3A cells (designated FM3A/0) were derived from a spontaneous 
murine mammary carcinoma in a C3H/He mouse [13]. FM3A TK- 
cells, selected for resistance against 5-bromo-2'-deoxyuridine and lack- 
ing host cell TK activity, were maintained inRPMI 1640 culture me- 
dium containing 10% fetal calf serum and 2 mM I.-glutamine, asde- 
scribed previously for the wild-type FM3A/0 cells [13,14]. The FM3A 
TK-/HSV-1 TK ÷ and FM3A TK-/HSV-2 TK ÷ cell lines, lacking cellu- 
lar TK activity but containing the HSV-1 and HSV-2 TK genes, respec- 
tively, were derived from FM3A TK cells as reported earlier [14,15]. 
The culture conditions for the cells were as described above. 
2.2. Compounds 
The synthesis ofthe test compounds (AzVDU, AzC 1EAU, AzlEAU 
and AzBrEAU) (Fig. 1) will be described elsewhere. 
2.3. Radiochemicals 
[5-3H]dCyd (specific radioactivity 20.1 Ci/mmol) was obtained from 
the Radiochemical Centre (Amersham, UK) and Moravek Biochemi- 
cals Inc. (Brea, CA). 
2.4. Anti-HSV-1, HSV-2, VZV and CMV activity of the test compounds 
in cell culture 
The procedure for measuring antiviral activity in human skin embryo 
fibroblast (E6SM) and human embryonic lung fibroblast (HEL) cells 
has been described previously [17,18]. The assay was based on HSV-1 
(strain KOS)-, HSV-1/TK- (strain VMW-1838)- and HSV-2 (strain 
G)-induced cytopathicity in E6SM monolayer cell cultures at day 3 post 
infection, or VZV (strains Oka and YS)-, VZV/TK- (07/1 and YS/R)- 
and CMV(strains ADI69 and Davis)-induced cytopathicity in HEL 
monolayer cells at day 7 post infection. The IC50 was defined as the 
compound concentration required to reduce virus-induced cytopathic- 
ity by 50%. 
2.5. Inhibition of cell proliferation by anti-herpetic drugs 
The methods for evaluating the cytostatic activity of the test com- 
pounds against the different FM3A cells were reported previously [16]. 
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Briefly, 5 × 10 4 cells suspended in growth medium were allowed to 
proliferate in 200-pl wells of microtiter plates in the presence of 5-fold 
dilutions of the test compounds at37°C in a humidified CO2-controlled 
atmosphere. After 48 h, the number of cells was counted in a Coulter 
counter (Harpenden, Hertz, UK). The IC50 was defined as the com- 
pound concentration required to inhibit FM3A cell proliferation by 
50%. 
2.6. Tritium release from [5JH]dCyd in FM3A cells 
Thymidylate synthase activity was measured in intact FM3A/0 and 
FM3A TK-/HSV-1 TK ÷ ceils by estimating tritium release from 
[5-3H]dUrd, which itself had been formed intracellularly from ex- 
ogenous [5-3H]dCyd. This procedure has been previously described in 
detail [17]. 
2. Z Irradiation of AzVDU-treated FM3A cell cultures 
FM3A/0 and FM3A/TK-/HSV-1 TK + cells were seeded in microtiter 
plate wells in the presence of serial dilutions of the test compounds as 
described above. Then, the microtiter plate was exposed to irradiation 
with a Sylvania lamp at A -- 366 nm or 254 nm at a fixed intensity of 
approximately 16lux for different time periods (i.e. 0, 1, 1.5, 2, 2.5, 3 
or 5 min). After irradiation, the cell cultures were incubated inthe dark 
at 37°C for 48 h after which the cell number was determined as de- 
scribed above. 
3. Results 
3.1. Antiviral activity of azido-substituted 2'-deoxyuridine and 
1-fl-D-arabinofuranosyluracil nalogues in cell culture 
5-(1-Azidovinyl)-2'-deoxyuridine (AzVDU) and 5-(1- 
azidoethyl)- 1-fl-D-arabinofuranosyluracil ana ogues containing 
a chloro (AzC1EAU), bromo (AzBrEAU) or iodo (AzlEAU) 
substituent in the C-2 position of the ethyl moiety were synthe- 
sized and evaluated for their anti-herpetic properties. As a rule, 
all the test compounds proved inhibitory to the replication of 
HSV-1 and VZV strains in human E6SM and HEL cell cultures, 
but not thymidine kinase-deficient (TK-) HSV-1 and VZV 
strains. The IC50 values of the test compounds ranged between 
0.4 and 1.8 pM for HSV-1 and 0.02 and 0.23 pM for VZV. 
Whereas the EAU derivatives were inhibitory to the CMV 
strains at an ICs0 that ranged between 1.45 and 10.4 pM, 
AzVDU and IVDU proved inactive against CMV at 20/zM. 
None of the test compounds were markedly inhibitory to the 
proliferation of E6SM or HEL cells (CC50:92 to > 100 pM). 
3.2. Inhibitory activity of  azido-substituted 2'-deoxyuridine and 
1-fl-D-arabinofuranosyluracil nalogues against murine 
mammary carcinoma FM3A cells 
The 5-(1-azido-2-halogeno)-EAU derivatives howed poor 
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Fig. 1. Structural formulae of AzVDU, IVDU and 5-(1-azido-2-halo- 
genovinyl)-2'-deoxyuridine analogues. 
cytostatic activity against wild-type FM3A/0 and the HSV-1- 
and HSV-2 TK  gene-transfected FM3A TK-/HSV TK + cell 
lines. Their IC50 ranged between 235 and 814/.tM (Table 2). 
However, in contrast with the EAU derivatives, AzVDU 
showed an increased cytostatic activity against FM3A TK-  
cells (~ 30-fold), and, even more so, against the HSV-1 and HSV- 
2 TK gene-transfected FM3A TK-  cells (~2000-fold and 8000- 
fold, respectively) (Table 2). The cytostatic activity of AzVDU 
against he latter two cell lines was thus 34  orders of magni- 
tude higher than against the parental FM3A/0 cells. In this 
respect, AzVDU behaved like IVDU, which also inhibited the 
growth of the HSV TK gene-transfected tumor cells at a 3,000- 
to 10,000-fold lower concentration than the parental tumor 
cells (Table 2). 
3.3. Molecular target of  the cytostatic activity of AzVDU 
against HSV TK gene-transfected FM3A cells 
The molecular target of the cytostatic action of IVDU had 
been previously identified as thymidylate synthase [2-5]. The 
activity of this enzyme in the intact cells can be quantified by 
measuring the tritium release from [5-3H]dCyd that is added to 
drug-exposed cell cultures [18]. Indeed, the tritium atom at the 
C-5 position of the cytosine ring is, upon deamination of dCyd 
Table 1 
Antiviral activity of 5-(1-azidovinyl)-2'-deoxyuridine a d5-(1-azido-2-halogenoethyl)-l-fl-D-arabinofuranosyluracils 
Compound IC50 ~M)" 
HSV-1 HSV-2 TK-/HSV-1 VZV TK-/VZV CMV 
(KOS) (G) (VMW 1837) (Oka,YS) (07/1,YS/R) (AD 169,Davis) 
CC50 O-tM) b 
(HEL) 
AzlEAU 0.46 161 460 0.11-0.21 > 11 2.3-4.6 92 
AzC 1EAU 0.58 > 580 - 580 0.02-0.04 > 15 1.45-3.48 100 
AzBrEAU 1.8 390 ->260 0.08-0.234 > 13 2.9-10.4 > 100 
AzVDU 0.4 150 > 400 0.1 > 50 > 20 > 200 
IVDU 0.02 70 10 0.001-0.002 10- > 50 > 20 90 
a50% inhibitory concentration r compound concentration required to inhibit HSV-1- and HSV-2-induced cytopathicity inhuman E6SM and VZV- 
and CMV-induced cytopathicity in human embryonic lung (HEL) fibroblasts by 50%. 
b50% cytotoxic oncentration r compound concentration required to inhibit HEL cell growth by 50%. All data represent means for at least 
2 independent experiments. 
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Table 2 
Inhibitory effects of [5-(1-azidovinyl)-2'-deoxyuridine and 5-(1-azido-2- 
halogenoethyl)-l-fl-I>arabinofuranosyluracils on the proliferation of 
murine mammary carcinoma (FM3A) cell lines transfected with the 
HSV-1 or HSV-2 thymidine kinase gene 
Compound IC50 (tiM) a 
FM3AJ0 FM3A/TK- FM3A TK-/ FM3A TK-/ 
HSV-1 TK ÷ HSV-2 TK ÷ 
AzIEAU 534 235 313 
AzC1EAU 658 400 531 
AzBrEAU 814 - 449 382 
AzVDU 183 5.5 0,087 0.022 
IVDU 18 0.40 0.005 0.002 
a50% inhibitory concentration r compound concentration required to 
inhibit FM3A cell proliferation by 50%. Data represent means for 2 3 
independent experiments. 
(or dCMP) to dUrd (or dUMP), replaced by a methyl group 
in the thymidylate synthase reaction (dUMP ~ dTMP + 3H30 )
and thus inhibition of thymidylate synthase can be monitored 
by inhibition of tritium release. Whereas AzVDU was not 
markedly inhibitory to tritium release from [5-3H]dCyd in 
FM3A/0 and FM3A TK-  cells, tritium release from [5-3H]dCyd 
was substantially inhibited in the HSV TK  gene-transfected 
FM3A tumor cells (Table 3). In fact, tritium release could be 
nearly 1000-fold more efficiently suppressed by AzVDU in the 
intact HSV TK  gene-transfected FM3A tumor cells than in the 
parental tumor cells. Thus, AzVDU proved only 5- to 10-fold 
less potent an inhibitor of thymidylate synthase in FM3A TK- /  
HSV TK  ÷ cells than IVDU. The data on inhibition ofthymidyl- 
ate synthase (tritium release) by both AzVDU and IVDU 
(Table 3) matched the cytostatic potency of the compounds 
(Table 2). 
3.4. Effect of light exposure on the cytostatic activity of AzVDU 
against HSV TK gene-transfeeted FM3A cells 
FM3A/0 and FM3A TK-/HSV-1 TK  + cell cultures to which 
AzVDU had been added were exposed to light of long wave- 
length (A = 366 nm) or short wavelength (A = 254 nm) for dif- 
ferent time periods (0-5 min). Under our experimental condi- 
tions, longer light-exposure times (particularly at A = 254 nm 
UV irradiation) resulted in a cytotoxic effect on the control cell 
cultures (data not shown). 
Irradiation at A = 366 nm did not affect he cytostatic activity 
of AzVDU against both FM3A/0 and FM3A TK-/HSV-1 TK  ÷ 
cells (Table 4). Also, irradiation of AzVDU-treated FM3A/0 
Table 3 
Inhibitory effects of AzVDU and IVDU on tritium release from 
[5-3H]dCyd in murine mammary carcinoma (FM3A) cell lines trans- 
fected with the HSV-1 or HSV-2 thymidine kinase gene 
Compound IC5o (ttM) a 
FM3AJ0 FM3A TK- FM3A TK-/ FM3A TK-/ 
HSV-1 TK + HSV-2 TK ÷ 
AzVDU 56 59 0.050 0.097 
IVDU 8.8 18 0.005 0.007 
a50% inhibitory concentration r compound concentration required to 
inhibit ritium release from [5-3H]dCyd in the intact FM3A tumor cells. 
Data represent means for 24  independent experiments. 
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Table 4 
Effect of irradiation (A = 254 or 366 nm) on the cytostatic activity of 
AzVDU against FM3A/0 and FM3A TK-/HSV-1 TK ÷ cells a 
Time of IC50 (tiM) b 
irradiation 
(min) FM3A/0 FM3ATK-/HSV-1TK ÷ 
254 nm 366 nm 254 nm 366 nm 
0 163 80 0.122 0.080 
1 93 77 0.044 0.097 
1.5 100 106 0.031 0.105 
2 72 84 0.024 0.078 
2.5 108 84 0.039 0.078 
3 144 76 0.022 0.074 
5 - 90 - 0.117 
~Irradiation of the drug-exposed cell cultures was started immediately 
after addition of the test compound at various concentrations. 
b50% inhibitory concentration r compound concentration required to 
inhibit FM3A cell proliferation by 50%. Data represent means for 
3 independent experiments. 
cells at A = 254 nm (UV) light did not alter the cytostatic activ- 
ity of the drug. However, exposure of AzVDU-treated FM3A 
TK-/HSV-1 TK ÷ cells to A = 254 nm (UV) light during 1-5 min, 
after which the cell cultures were further incubated in the dark 
for 48 h, resulted in a markedly increased cytostatic activity, as 
compared to the drug-treated cell cultures that were not ex- 
posed to UV light. Upon irradiation at A = 254 nm the cyto- 
static activity of AzVDU increased by 3- to 6-fold. This increase 
in cytostatic activity was even noted within one-minute of UV 
irradiation. 
4. Discussion 
Novel azido-substituted pyrimidine nucleoside analogues 
that are endowed with potent and selective antiherpetic proper- 
ties have been discovered. 
AzVDU, as well as the 5-(1-azido-2-halogenoethyl)-substi- 
tuted AU derivatives, are potent and selective inhibitors of 
herpes simplex virus type 1 and varicella zoster virus in cell 
cultures. In contrast with AzVDU and IVDU, AzlEAU, 
AzBrEAU and AzC1EAU also proved to be relatively potent 
inhibitors of cytomegalovirus infection. The activity of the test 
compounds against HSV-1 and VZV is dependent on the viral 
TK-mediated phosphorylation, as indicated by the lack of ac- 
tivity against TK-deficient HSV-1 or VZV strains. The herpetic 
TK-dependence of the intracellular activation of the test com- 
pounds is further corroborated by their poor cytostatic activity 
against uninfected cells. 
Interestingly, AzVDU, but not the 5-(l-azido-2-halo- 
genoethyl)arabinouridine erivatives, displayed a markedly in- 
creased cytostatic activity against both HSV-1 and HSV-2 TK 
gene-transfected tumor cells. As previously demonstrated for 
BVDU and its structurally closely related derivatives (i.e. 
IVDU), the cytostatic activity of AzVDU against HSV TK 
gene-transfected tumor cells is due to a specific inhibition of 
thymidylate synthase, a well-recognized target enzyme for anti- 
tumor chemotherapy [18]. The cytostatic activity of AzVDU 
against hese tumor cell lines could be further enhanced upon 
short-time xposure to UV light (2 = 254 nm). This may open 
interesting perspectives in the treatment of some cutaneous 
disorders uch as malignant melanoma. Combination of HSV-1 
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TK gene therapy with anti-herpetic hemotherapy has been 
recently introduced in brain tumor-bearing animals that were 
first intra-tumorally exposed to murine fibroblasts (containing 
a retroviral vector in which the HSV-1 TK gene had been 
inserted), and then treated with the anti-herpetic drug ganci- 
clovir [8-11]. This concept is now being further explored in 
experimental tumor models, including malignant melanomas. 
Our findings that UV-light exposure of purified herpetic thy- 
midine kinase in the presence of AzVDU did not affect the 
activity of the enzyme (data not shown) provide further evi- 
dence that the increased cytostatic activity observed in the 
irradiated drug-treated tumor cell cultures is not due to an 
altered TK activity (i.e. by increased phosphorylation of the test 
compound), but most likely to an increased inhibitory effect of 
the irradiated test compound on the thymidylate synthase in the 
HSV TK gene-transfected tumor cells. 
From our earlier observations we know that BVaraU, the 
arabinosyl derivative of BVDU, is a potent anti-herpetic agent, 
being endowed with a high affinity for the HSV- and VZV- 
encoded TK. However, BVaraU is not markedly cytostatic 
against HSV TK gene-transfected FM3A cells. The inactivity 
of BVaraU against he HSV TK gene-transfected FM3A tumor 
cells could be ascribed to the virtual lack of affinity of BVaraU 
5'-monophosphate against thymidylate synthase [19]. There- 
fore, the inactivity of the 5-(1-azido-2-halogenoethyl)-l-fl-D- 
arabinofuranosyluracil derivatives included in this study 
against the FM3A TK-/HSV-TK + cells could be most likely 
ascribed to the same phenomenon as observed for BVaraU. 
This failure of the arabinofuranosyluracil derivatives against 
the HSV TK gene transfected tumor cells to be endowed with 
a marked cytostatic potential provide further evidence for the 
role of thymidylate synthase as the target enzyme in the cyto- 
static activity of AzVDU against FM3A TK-/HSV TK + cells. 
In conclusion, our photoaffinity approach may open new 
perspectives for the treatment of cutaneous disorders uch as 
malignant melanoma with respect o azido-based chemother- 
apeutic agents that show increased cytostatic activity against 
HSV TK gene-transfected tumor cells upon short (i.e. 1-min) 
UV light exposure. 
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